{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:42:12Z","timestamp":1740109332637,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Chronisch nierenkranke Patienten weisen eine erh\u00f6hte kardiovaskul\u00e4re Morbidit\u00e4t und Sterblichkeit auf. Im letzten Jahr sind einige wichtige Studien zur Herz-Nieren-Interaktion ver\u00f6ffentlicht worden, die im Folgenden zusammengefasst und diskutiert werden. In der DAPA-CKD-Studie sowie in der SCORED-Studie konnten 2 unterschiedliche SGLT2(\u201esodium-glucose linked transporter 2\u201c)-Inhibitoren (Dapagliflozin und Sotagliflozin) die Prognose von chronisch nierenkranken Patienten mit und ohne Diabetes nachweislich verbessern. Auch die Ergebnisse der randomisierten Studie zum neuen Mineralokortikoidrezeptorantagonisten Finerenon \u2013\u00a0FIDELIO-DKD\u00a0\u2013 liefern einen vielversprechenden neuen Therapieansatz f\u00fcr Patienten mit diabetischer Nephropathie. Die ver\u00f6ffentlichten Daten der ISCHEMIA-CKD-Studie bei Patienten mit koronarer Herzkrankheit und Untersuchungen zum Einfluss einer TAVI (\u201etranscatheter aortic valve implantation\u201c) auf die Nierenfunktion sowie eine weitere Studie zum akuten Nierenversagen nach MitraClip\u00ae-Implantation (Abbott, Chicago, IL, USA) geben wichtige Hinweise zu zuk\u00fcnftigen Handlungsempfehlungen. Der optimale Zeitpunkt der Einleitung einer Nierenersatztherapie bei Patienten mit akuter Nierensch\u00e4digung in der Intensivmedizin wurde in 2\u00a0randomisierten Studien untersucht, die entsprechend diskutiert werden.<\/jats:p>","DOI":"10.1007\/s00059-021-05043-0","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T12:06:35Z","timestamp":1623240395000},"page":"150-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelles zur Herz-Nieren-Interaktion","Current aspects of heart-kidney interactions"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5048-3659","authenticated-orcid":false,"given":"Insa E.","family":"Emrich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mert","family":"Tokcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussam","family":"Al Ghorani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedat","family":"Schwenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"5043_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/eurjhf\/hfq077","volume":"12","author":"K Hebert","year":"2010","unstructured":"Hebert\u00a0K, Dias\u00a0A, Delgado\u00a0MC et\u00a0al (2010) Epidemiology and survival of the five stages of chronic kidney disease in a\u00a0systolic heart failure population. Eur J Heart Fail 12:861\u2013865. https:\/\/doi.org\/10.1093\/eurjhf\/hfq077","journal-title":"Eur J Heart Fail"},{"key":"5043_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","volume":"102","author":"HL Hillege","year":"2000","unstructured":"Hillege\u00a0HL, Girbes\u00a0ARJ, De Kam\u00a0PJ et\u00a0al (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102:203\u2013210. https:\/\/doi.org\/10.1161\/01.CIR.102.2.203","journal-title":"Circulation"},{"key":"5043_CR3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00108-019-00692-0","volume":"61","author":"S Ewen","year":"2020","unstructured":"Ewen\u00a0S, Mahfoud\u00a0F, Lauder\u00a0L et\u00a0al (2020) Valvular heart disease in patients with chronic kidney disease. Internist 61:368\u2013374","journal-title":"Internist"},{"key":"5043_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-019-04846-6","author":"L Lauder","year":"2019","unstructured":"Lauder\u00a0L, Ewen\u00a0S, Emrich\u00a0IE et al (2019) Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure. Herz. https:\/\/doi.org\/10.1007\/s00059-019-04846-6","journal-title":"Herz"},{"key":"5043_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM et\u00a0al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N\u00a0Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"5043_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C, Inzucchi\u00a0SE, Lachin\u00a0JM et\u00a0al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N\u00a0Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/nejmoa1515920","journal-title":"N Engl J Med"},{"key":"5043_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/nejmoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N\u00a0Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/nejmoa2022190","journal-title":"N Engl J Med"},{"key":"5043_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffey\u00a0KW et\u00a0al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"5043_CR9","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, Jardine\u00a0MJ, Neal\u00a0B et\u00a0al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N\u00a0Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"5043_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","author":"SD Wiviott","year":"2018","unstructured":"Wiviott\u00a0SD, Raz\u00a0I, Bonaca\u00a0MP et\u00a0al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"5043_CR11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"5043_CR12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/nejmoa2024816","journal-title":"N Engl J Med"},{"key":"5043_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/nejmoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt\u00a0DL, Szarek\u00a0M, Pitt\u00a0B et\u00a0al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N\u00a0Engl J Med 384:129\u2013139. https:\/\/doi.org\/10.1056\/nejmoa2030186","journal-title":"N Engl J Med"},{"key":"5043_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000290","volume":"26","author":"O Al Dhaybi","year":"2017","unstructured":"Al Dhaybi\u00a0O, Bakris\u00a0G (2017) Mineralocorticoid antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens 26:50\u201355","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5043_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med 383:2219\u20132229. https:\/\/doi.org\/10.1056\/nejmoa2025845","journal-title":"N Engl J Med"},{"key":"5043_CR16","unstructured":"KDIGO (2020) Hypertension guidelines. https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO. Zugegriffen: 14.\u00a0Feb. 2021"},{"key":"5043_CR17","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung\u00a0AK, Rahman\u00a0M, Reboussin\u00a0DM et\u00a0al (2017) Effects of intensive BP control in CKD. J\u00a0Am Soc Nephrol 28:2812\u20132823. https:\/\/doi.org\/10.1681\/ASN.2017020148","journal-title":"J Am Soc Nephrol"},{"key":"5043_CR18","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright","year":"2015","unstructured":"Wright\u00a0JT, Williamson\u00a0JD, Whelton\u00a0PK et\u00a0al (2015) SPRINT Trial. N\u00a0Engl J Med 373:2103\u20132116. https:\/\/doi.org\/10.1056\/NEJMoa1511939","journal-title":"N Engl J Med"},{"key":"5043_CR19","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group; Cushman\u00a0WC, Evans\u00a0GW, Byington\u00a0RP (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N\u00a0Engl J Med 362:1575\u20131585. https:\/\/doi.org\/10.1056\/NEJMoa1001286","journal-title":"N Engl J Med"},{"key":"5043_CR20","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1161\/CIR.0000000000000596","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton\u00a0PK, Carey\u00a0RM, Aronow\u00a0WS et\u00a0al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 138:e484\u2013e594. https:\/\/doi.org\/10.1161\/CIR.0000000000000596","journal-title":"Circulation"},{"key":"5043_CR21","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W et\u00a0al (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart\u00a0J 39:3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"key":"5043_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz381","author":"IE Emrich","year":"2019","unstructured":"Emrich\u00a0IE, B\u00f6hm\u00a0M, Mahfoud\u00a0F (2019) The 2018 ESC\/ESH guidelines for the management of arterial hypertension: a German point of view. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz381","journal-title":"Eur Heart J"},{"key":"5043_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao\u00a0Y, Shin\u00a0JI, Chen\u00a0TK et al (2020) Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 180:718\u2013726. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0193","journal-title":"JAMA Intern Med"},{"key":"5043_CR24","doi-asserted-by":"publisher","first-page":"e009980","DOI":"10.1161\/JAHA.118.009980","volume":"8","author":"KK Patel","year":"2019","unstructured":"Patel\u00a0KK, Shah\u00a0SY, Arrigain\u00a0S et\u00a0al (2019) Characteristics and outcomes of patients with aortic stenosis and chronic kidney disease. J\u00a0Am Heart Assoc 8:e9980. https:\/\/doi.org\/10.1161\/JAHA.118.009980","journal-title":"J Am Heart Assoc"},{"key":"5043_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jacc.2020.07.048","volume":"76","author":"RJ Cubeddu","year":"2020","unstructured":"Cubeddu\u00a0RJ, Asher\u00a0CR, Lowry\u00a0AM et\u00a0al (2020) Impact of transcatheter aortic valve replacement on severity of chronic kidney disease. J\u00a0Am Coll Cardiol 76:1410\u20131421. https:\/\/doi.org\/10.1016\/j.jacc.2020.07.048","journal-title":"J Am Coll Cardiol"},{"key":"5043_CR26","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.jacc.2020.09.582","volume":"76","author":"G Armijo","year":"2020","unstructured":"Armijo\u00a0G, Estevez-Loureiro\u00a0R, Carrasco-Chinchilla\u00a0F et al (2020) Acute kidney injury after percutaneous edge-to-edge mitral repair. J\u00a0Am Coll Cardiol 76:2463\u20132473. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.582","journal-title":"J Am Coll Cardiol"},{"key":"5043_CR27","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","volume":"394","author":"C Ronco","year":"2019","unstructured":"Ronco\u00a0C, Bellomo\u00a0R, Kellum\u00a0JA (2019) Acute kidney injury. Lancet 394:1949\u20131964","journal-title":"Lancet"},{"key":"5043_CR28","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S0140-6736(20)30531-6","volume":"395","author":"S Gaudry","year":"2020","unstructured":"Gaudry\u00a0S, Hajage\u00a0D, Benichou\u00a0N et al (2020) Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a\u00a0systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet 395:1506\u20131515. https:\/\/doi.org\/10.1016\/S0140-6736(20)30531-6","journal-title":"Lancet"},{"key":"5043_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/nejmoa1603017","volume":"375","author":"S Gaudry","year":"2016","unstructured":"Gaudry\u00a0S, Hajage\u00a0D, Schortgen\u00a0F et al (2016) Initiation strategies for renal-replacement therapy in the intensive care unit. N\u00a0Engl J Med 375:122\u2013133. https:\/\/doi.org\/10.1056\/nejmoa1603017","journal-title":"N Engl J Med"},{"key":"5043_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/nejmoa1803213","volume":"379","author":"SD Barbar","year":"2018","unstructured":"Barbar\u00a0SD, Clere-Jehl\u00a0R, Bourredjem\u00a0A et al (2018) Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N\u00a0Engl J Med 379:1431\u20131442. https:\/\/doi.org\/10.1056\/nejmoa1803213","journal-title":"N Engl J Med"},{"key":"5043_CR31","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1056\/nejmoa2000741","volume":"383","author":"The STARRT-AKI Investigators for the Canadian Critical Care Trials Group","year":"2020","unstructured":"The STARRT-AKI Investigators for the Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group, United Kingdom Critical Care Research Group, Canadian Nephrology Trials Network,, Irish Critical Care Trials Group (2020) Timing of initiation of renal-replacement therapy in acute kidney injury. N\u00a0Engl J Med 383:240\u2013251. https:\/\/doi.org\/10.1056\/nejmoa2000741","journal-title":"N Engl J Med"},{"key":"5043_CR32","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/nejmoa1915925","volume":"382","author":"S Bangalore","year":"2020","unstructured":"Bangalore\u00a0S, Maron\u00a0DJ, O\u2019Brien\u00a0SM et\u00a0al (2020) Management of coronary disease in patients with advanced kidney disease. N\u00a0Engl J Med 382:1608\u20131618. https:\/\/doi.org\/10.1056\/nejmoa1915925","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05043-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T16:54:13Z","timestamp":1648227253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05043-0"}},"subtitle":["Zusammenfassung wichtiger klinischer Studien aus 2020","Summary of important clinical studies from 2020"],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5043"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05043-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Mahfoud gibt an, Forschungsunterst\u00fctzung und Vortragshonorare von Medtronic, Recor, Berlin Chemie und Boehringer Ingelheim erhalten zu haben und durch die Deutsche Forschungsgemeinschaft (SFB-TRR219) unterst\u00fctzt zu werden. I.\u00a0Emrich gibt an, Vortragshonorare von Pharmacosmos erhalten zu haben. M.\u00a0Tokcan, H.\u00a0Al Ghorani und V.\u00a0Schwenger geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}